News of Note—Gritstone’s EVP, Trump’s opioid vaccine plan and more

In this week's news of note, Gritstone Oncology hired an industry veteran as its technical operations head. (Pixabay)

Here's some other vaccine news of note for the week.

> Cancer vaccine startup Gritstone Oncology hired Jayant Aphale, Ph.D., as EVP of technical operations. He previously served senior roles at Sarepta, GlaxoSmithKline Vaccines, Acambis and Wyeth Vaccines. Release

> President Donald Trump unveiled a new plan to combat the opioid crisis, including support for research into developing a vaccine for opioid addiction. CNBC article

> The Philippine government will seek congressional permission to use refunds for unused Dengvaxia shots from Sanofi to support related medical needs of those already inoculated. ABS-CBN article

> TapImmune’s shares rose 17% premarket Thursday after the company said its TPIV200 T-cell vaccine did well in a phase 1 study in patients with ovarian and breast cancer. MarketWatch article